Cloudbreak Pharmaceutical is a clinical-stage biotechnology company focusing on ocular drug development.
Our mission is to help people see life better through medicine.
About Us
Cloudbreak Pharmaceutical is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.
Our Focus
Cloudbreak Pharmaceutical has successfully formulated a potent multi-kinase inhibitor to block angiogenesis and fibrosis into a topical eye drop to treat anterior segment ophthalmic diseases. In addition, Cloudbreak Pharmaceutical has a unique Antibody-Drug Synergism Platform to treat posterior segment ophthalmic diseases.
Pipeline
Cloudbreak Pharmaceutical has a number of products at various stages of pre-clinical and clinical development that treat pterygium, pinguecula, meibomian gland dysfunction, glaucoma filtration surgery, adjunct therapy for glaucoma filtration surgery, age-related macular degeneration and diabetic retinopathy.